Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Stauffer

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Bone Marrow Transplantation|February 6, 2022
Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCTSimon Husby, Gustav Ø Jørgensen, Francesco Favero, et al.
Blood Neoplasia|June 27, 2025
Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodiesEmil Ramsø Kyvsgaard, Trine Lønbo Grantzau, Mia Dahl Sørensen, et al.
Leukemia & Lymphoma|September 3, 2024
The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide studyMikkel Runason Simonsen, Laura Mors Haunstrup, Freja Tang Severinsen, et al.
Plos One|September 1, 2016
A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic MyelofibrosisVibe Skov, Mark Burton, Mads Thomassen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II TrialMartin Hutchings, Anna Sureda, Francesc Bosch, et al.
Hemasphere|May 13, 2025
Biomarker-adapted treatment in high-risk large B-cell lymphomaSirpa Leppä, Leo Meriranta, Maare Arffman, et al.
Ejhaem|January 27, 2025
The long-term risk of immune-related conditions in survivors of diffuse large B-cell lymphoma: A Danish nationwide registry studyLaura Schou Pedersen, Nadja Nørholm Klausen, Jonas Faartoft Jensen, et al.
Cancer Medicine|June 23, 2018
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosisStine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
Clinical Epidemiology|March 21, 2023
Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort StudyEva Futtrup Maksten, Lasse Hjort Jakobsen, Kristian Hay Kragholm, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Bone Marrow Transplantation|February 6, 2022
Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCTSimon Husby, Gustav Ø Jørgensen, Francesco Favero, et al.
Blood Neoplasia|June 27, 2025
Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodiesEmil Ramsø Kyvsgaard, Trine Lønbo Grantzau, Mia Dahl Sørensen, et al.
Leukemia & Lymphoma|September 3, 2024
The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide studyMikkel Runason Simonsen, Laura Mors Haunstrup, Freja Tang Severinsen, et al.
Plos One|September 1, 2016
A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic MyelofibrosisVibe Skov, Mark Burton, Mads Thomassen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II TrialMartin Hutchings, Anna Sureda, Francesc Bosch, et al.
Hemasphere|May 13, 2025
Biomarker-adapted treatment in high-risk large B-cell lymphomaSirpa Leppä, Leo Meriranta, Maare Arffman, et al.
Ejhaem|January 27, 2025
The long-term risk of immune-related conditions in survivors of diffuse large B-cell lymphoma: A Danish nationwide registry studyLaura Schou Pedersen, Nadja Nørholm Klausen, Jonas Faartoft Jensen, et al.
Cancer Medicine|June 23, 2018
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosisStine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
Clinical Epidemiology|March 21, 2023
Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort StudyEva Futtrup Maksten, Lasse Hjort Jakobsen, Kristian Hay Kragholm, et al.
Pageof 11